Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02214173 · ClinicalTrials.gov registry record · NA
The Effect of an Enhanced Rice Bran Nutritional Supplement in HIV
A NA study of Human Immunodeficiency Virus Infection, sponsored by University of Miami.
- Completed
- Registry status
- NA
- Development phase
- 47
- Enrollment target
- 1
- Study location
NCT02214173 is a NA study of Human Immunodeficiency Virus Infection that has completed, run by University of Miami. The registered enrollment target is 47 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02214173, a NA study of Human Immunodeficiency Virus Infection, has completed, sponsored by University of Miami.
- COMPLETED
- Registry status
- NA
- Development phase
- 47 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to investigate the effects of the nutritional supplement rice bran arabinoxylan compound (RBAC) on metabolic syndrome variables in persons living with HIV. The hypothesis is that there will be a significant improvement in metabolic syndrome and immune variables in HIV-positive participants in the intervention group compared to the control group.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT rice bran arabinoxylan compound (RBAC)
Study Locations (1)
Florida
- University of Miami Miller School of Medicine, Clinical Research Building, Department of Psychiatry & Behavioral Sciences - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2015-01 |
| Est. Completion | 2016-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02214173
The ClinicalTrials.gov registry entry for NCT02214173 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Human Immunodeficiency Virus Infection appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02214173 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT02214173 about?
NCT02214173 is a clinical study titled "The Effect of an Enhanced Rice Bran Nutritional Supplement in HIV". The purpose of this study is to investigate the effects of the nutritional supplement rice bran arabinoxylan compound (RBAC) on metabolic syndrome variables in persons living with HIV. The hypothesis is that there will be a significant improvement in metabolic syndrome and immune variables in HIV-po...
What is the current status of trial NCT02214173?
This trial is currently completed. It is a NA study. The enrollment target is 47 participants. The study started on 2015-01. Estimated completion is 2016-06.
What conditions does trial NCT02214173 study?
This clinical trial studies the following conditions: Human Immunodeficiency Virus Infection.
What interventions are being tested in trial NCT02214173?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), rice bran arabinoxylan compound (RBAC) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02214173?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02214173 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.